Global Pneumococcal Conjugate Vaccine (PCV) Supply, Demand and Key Producers, 2023-2029

Page: 97

Published Date: 15 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Pneumococcal Conjugate Vaccine (PCV) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Pneumococcal Conjugate Vaccine (PCV) demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Pneumococcal Conjugate Vaccine (PCV), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pneumococcal Conjugate Vaccine (PCV) that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Pneumococcal Conjugate Vaccine (PCV) total market, 2018-2029, (USD Million)
Global Pneumococcal Conjugate Vaccine (PCV) total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Pneumococcal Conjugate Vaccine (PCV) total market, key domestic companies and share, (USD Million)
Global Pneumococcal Conjugate Vaccine (PCV) revenue by player and market share 2018-2023, (USD Million)
Global Pneumococcal Conjugate Vaccine (PCV) total market by Type, CAGR, 2018-2029, (USD Million)
Global Pneumococcal Conjugate Vaccine (PCV) total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Pneumococcal Conjugate Vaccine (PCV) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic and Serum Institute of India, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Pneumococcal Conjugate Vaccine (PCV) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Pneumococcal Conjugate Vaccine (PCV) Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Pneumococcal Conjugate Vaccine (PCV) Market, Segmentation by Type
    23-valent Vaccine
    10-valent Vaccine
    7-valent Vaccine
    13-valent Vaccine

Global Pneumococcal Conjugate Vaccine (PCV) Market, Segmentation by Application
    Child
    Adult

Companies Profiled:
    Pfizer
    GSK
    Sanofi
    Merck
    Walvax Biotechnology
    Royal (Wuxi) Bio-Pharmaceutical
    Zhifei Biologic
    Serum Institute of India

Key Questions Answered
1. How big is the global Pneumococcal Conjugate Vaccine (PCV) market?
2. What is the demand of the global Pneumococcal Conjugate Vaccine (PCV) market?
3. What is the year over year growth of the global Pneumococcal Conjugate Vaccine (PCV) market?
4. What is the total value of the global Pneumococcal Conjugate Vaccine (PCV) market?
5. Who are the major players in the global Pneumococcal Conjugate Vaccine (PCV) market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Pneumococcal Conjugate Vaccine (PCV) Introduction
    1.2 World Pneumococcal Conjugate Vaccine (PCV) Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Pneumococcal Conjugate Vaccine (PCV) Total Market by Region (by Headquarter Location)
        1.3.1 World Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
        1.3.3 China Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
        1.3.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
        1.3.5 Japan Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
        1.3.6 South Korea Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
        1.3.7 ASEAN Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
        1.3.8 India Pneumococcal Conjugate Vaccine (PCV) Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Pneumococcal Conjugate Vaccine (PCV) Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Pneumococcal Conjugate Vaccine (PCV) Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.2 World Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region
        2.2.1 World Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2018-2023)
        2.2.2 World Pneumococcal Conjugate Vaccine (PCV) Consumption Value Forecast by Region (2024-2029)
    2.3 United States Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.4 China Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.5 Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.6 Japan Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.7 South Korea Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.8 ASEAN Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)
    2.9 India Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029)

3 World Pneumococcal Conjugate Vaccine (PCV) Companies Competitive Analysis
    3.1 World Pneumococcal Conjugate Vaccine (PCV) Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Pneumococcal Conjugate Vaccine (PCV) in 2022
        3.2.3 Global Concentration Ratios (CR8) for Pneumococcal Conjugate Vaccine (PCV) in 2022
    3.3 Pneumococcal Conjugate Vaccine (PCV) Company Evaluation Quadrant
    3.4 Pneumococcal Conjugate Vaccine (PCV) Market: Overall Company Footprint Analysis
        3.4.1 Pneumococcal Conjugate Vaccine (PCV) Market: Region Footprint
        3.4.2 Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Type Footprint
        3.4.3 Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Pneumococcal Conjugate Vaccine (PCV) Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Pneumococcal Conjugate Vaccine (PCV) Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Pneumococcal Conjugate Vaccine (PCV) Consumption Value Comparison
        4.2.1 United States VS China: Pneumococcal Conjugate Vaccine (PCV) Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Pneumococcal Conjugate Vaccine (PCV) Companies and Market Share, 2018-2023
        4.3.1 United States Based Pneumococcal Conjugate Vaccine (PCV) Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue, (2018-2023)
    4.4 China Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue and Market Share, 2018-2023
        4.4.1 China Based Pneumococcal Conjugate Vaccine (PCV) Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue, (2018-2023)
    4.5 Rest of World Based Pneumococcal Conjugate Vaccine (PCV) Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Pneumococcal Conjugate Vaccine (PCV) Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 23-valent Vaccine
        5.2.2 10-valent Vaccine
        5.2.3 7-valent Vaccine
        5.2.4 13-valent Vaccine
    5.3 Market Segment by Type
        5.3.1 World Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2018-2023)
        5.3.2 World Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2024-2029)
        5.3.3 World Pneumococcal Conjugate Vaccine (PCV) Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Pneumococcal Conjugate Vaccine (PCV) Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Child
        6.2.2 Adult
    6.3 Market Segment by Application
        6.3.1 World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2018-2023)
        6.3.2 World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2024-2029)
        6.3.3 World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Details
        7.1.2 Pfizer Major Business
        7.1.3 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.1.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Pfizer Recent Developments/Updates
        7.1.6 Pfizer Competitive Strengths & Weaknesses
    7.2 GSK
        7.2.1 GSK Details
        7.2.2 GSK Major Business
        7.2.3 GSK Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.2.4 GSK Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 GSK Recent Developments/Updates
        7.2.6 GSK Competitive Strengths & Weaknesses
    7.3 Sanofi
        7.3.1 Sanofi Details
        7.3.2 Sanofi Major Business
        7.3.3 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.3.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Sanofi Recent Developments/Updates
        7.3.6 Sanofi Competitive Strengths & Weaknesses
    7.4 Merck
        7.4.1 Merck Details
        7.4.2 Merck Major Business
        7.4.3 Merck Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.4.4 Merck Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Merck Recent Developments/Updates
        7.4.6 Merck Competitive Strengths & Weaknesses
    7.5 Walvax Biotechnology
        7.5.1 Walvax Biotechnology Details
        7.5.2 Walvax Biotechnology Major Business
        7.5.3 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.5.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Walvax Biotechnology Recent Developments/Updates
        7.5.6 Walvax Biotechnology Competitive Strengths & Weaknesses
    7.6 Royal (Wuxi) Bio-Pharmaceutical
        7.6.1 Royal (Wuxi) Bio-Pharmaceutical Details
        7.6.2 Royal (Wuxi) Bio-Pharmaceutical Major Business
        7.6.3 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.6.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
        7.6.6 Royal (Wuxi) Bio-Pharmaceutical Competitive Strengths & Weaknesses
    7.7 Zhifei Biologic
        7.7.1 Zhifei Biologic Details
        7.7.2 Zhifei Biologic Major Business
        7.7.3 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.7.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Zhifei Biologic Recent Developments/Updates
        7.7.6 Zhifei Biologic Competitive Strengths & Weaknesses
    7.8 Serum Institute of India
        7.8.1 Serum Institute of India Details
        7.8.2 Serum Institute of India Major Business
        7.8.3 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product and Services
        7.8.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Serum Institute of India Recent Developments/Updates
        7.8.6 Serum Institute of India Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Pneumococcal Conjugate Vaccine (PCV) Industry Chain
    8.2 Pneumococcal Conjugate Vaccine (PCV) Upstream Analysis
    8.3 Pneumococcal Conjugate Vaccine (PCV) Midstream Analysis
    8.4 Pneumococcal Conjugate Vaccine (PCV) Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Pneumococcal Conjugate Vaccine (PCV) Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Pneumococcal Conjugate Vaccine (PCV) Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Pneumococcal Conjugate Vaccine (PCV) Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Pneumococcal Conjugate Vaccine (PCV) Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Pneumococcal Conjugate Vaccine (PCV) Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Pneumococcal Conjugate Vaccine (PCV) Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Pneumococcal Conjugate Vaccine (PCV) Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Pneumococcal Conjugate Vaccine (PCV) Players in 2022
    Table 12. World Pneumococcal Conjugate Vaccine (PCV) Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Pneumococcal Conjugate Vaccine (PCV) Company Evaluation Quadrant
    Table 14. Head Office of Key Pneumococcal Conjugate Vaccine (PCV) Player
    Table 15. Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Type Footprint
    Table 16. Pneumococcal Conjugate Vaccine (PCV) Market: Company Product Application Footprint
    Table 17. Pneumococcal Conjugate Vaccine (PCV) Mergers & Acquisitions Activity
    Table 18. United States VS China Pneumococcal Conjugate Vaccine (PCV) Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Pneumococcal Conjugate Vaccine (PCV) Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Pneumococcal Conjugate Vaccine (PCV) Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share (2018-2023)
    Table 23. China Based Pneumococcal Conjugate Vaccine (PCV) Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Pneumococcal Conjugate Vaccine (PCV) Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share (2018-2023)
    Table 29. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2024-2029) & (USD Million)
    Table 35. Pfizer Basic Information, Area Served and Competitors
    Table 36. Pfizer Major Business
    Table 37. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 38. Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Pfizer Recent Developments/Updates
    Table 40. Pfizer Competitive Strengths & Weaknesses
    Table 41. GSK Basic Information, Area Served and Competitors
    Table 42. GSK Major Business
    Table 43. GSK Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 44. GSK Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. GSK Recent Developments/Updates
    Table 46. GSK Competitive Strengths & Weaknesses
    Table 47. Sanofi Basic Information, Area Served and Competitors
    Table 48. Sanofi Major Business
    Table 49. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 50. Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Sanofi Recent Developments/Updates
    Table 52. Sanofi Competitive Strengths & Weaknesses
    Table 53. Merck Basic Information, Area Served and Competitors
    Table 54. Merck Major Business
    Table 55. Merck Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 56. Merck Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Merck Recent Developments/Updates
    Table 58. Merck Competitive Strengths & Weaknesses
    Table 59. Walvax Biotechnology Basic Information, Area Served and Competitors
    Table 60. Walvax Biotechnology Major Business
    Table 61. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 62. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Walvax Biotechnology Recent Developments/Updates
    Table 64. Walvax Biotechnology Competitive Strengths & Weaknesses
    Table 65. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Area Served and Competitors
    Table 66. Royal (Wuxi) Bio-Pharmaceutical Major Business
    Table 67. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 68. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
    Table 70. Royal (Wuxi) Bio-Pharmaceutical Competitive Strengths & Weaknesses
    Table 71. Zhifei Biologic Basic Information, Area Served and Competitors
    Table 72. Zhifei Biologic Major Business
    Table 73. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 74. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Zhifei Biologic Recent Developments/Updates
    Table 76. Serum Institute of India Basic Information, Area Served and Competitors
    Table 77. Serum Institute of India Major Business
    Table 78. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product and Services
    Table 79. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 80. Global Key Players of Pneumococcal Conjugate Vaccine (PCV) Upstream (Raw Materials)
    Table 81. Pneumococcal Conjugate Vaccine (PCV) Typical Customers
List of Figure
    Figure 1. Pneumococcal Conjugate Vaccine (PCV) Picture
    Figure 2. World Pneumococcal Conjugate Vaccine (PCV) Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Pneumococcal Conjugate Vaccine (PCV) Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Pneumococcal Conjugate Vaccine (PCV) Revenue (2018-2029) & (USD Million)
    Figure 13. Pneumococcal Conjugate Vaccine (PCV) Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Pneumococcal Conjugate Vaccine (PCV) Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Pneumococcal Conjugate Vaccine (PCV) by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Pneumococcal Conjugate Vaccine (PCV) Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Pneumococcal Conjugate Vaccine (PCV) Markets in 2022
    Figure 27. United States VS China: Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Pneumococcal Conjugate Vaccine (PCV) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Pneumococcal Conjugate Vaccine (PCV) Market Size Market Share by Type in 2022
    Figure 31. 23-valent Vaccine
    Figure 32. 10-valent Vaccine
    Figure 33. 7-valent Vaccine
    Figure 34. 13-valent Vaccine
    Figure 35. World Pneumococcal Conjugate Vaccine (PCV) Market Size Market Share by Type (2018-2029)
    Figure 36. World Pneumococcal Conjugate Vaccine (PCV) Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 37. World Pneumococcal Conjugate Vaccine (PCV) Market Size Market Share by Application in 2022
    Figure 38. Child
    Figure 39. Adult
    Figure 40. Pneumococcal Conjugate Vaccine (PCV) Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Pneumococcal Conjugate Vaccine (PCV) Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Pneumococcal Conjugate Vaccine (PCV) Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 05 Jan 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Pneumococcal Conjugate Vaccine (PCV) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Pneumococcal Conjugate Vaccine (PCV) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Pneumococcal Conjugate Vaccine (PCV) Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 15 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Pneumococcal Conjugate Vaccine (PCV) market size was valued at USD 4257.8 million in 2023 and is forecast to a readjusted size of USD 5258.8 million by 2030 with a CAGR of 3.1% during review period.

Product Tags

Pneumococcal Conjugate Vaccine (PCV)

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>